Post by NBE-Therapeutics AG

AACR San Diego: advancing ADC innovation—together We’re excited to share that NBE Therapeutics AG is attending the AACR Annual Meeting in San Diego. It’s a great opportunity to connect with the oncology community and exchange perspectives on where innovation is accelerating fastest. Our focus are the most recent advantages in antibody–drug conjugate (ADC) preclinical development—spanning smarter target and payload selection, more predictive translational models, and cutting-edge technologies that help de-risk candidates earlier while increasing the quality of decision-making. While attending, we take the chance to nurture and expand our network—both with internal colleagues from Boehringer Ingelheim and with external partners across academia and industry. We’re especially keen to connect and continue the conversations beyond San Diego to help advance the next generation of targeted cancer therapies. #AACR #AntibodyDrugConjugates #Oncology #PreclinicalDevelopment #BoehringerIngelheim